文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Aficamten与美托洛尔对梗阻性肥厚型心肌病患者报告健康状况的影响

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2025-11-18

MAPLE-HCM随机双盲试验纳入175例有症状梗阻性肥厚型心肌病患者,比较Aficamten与美托洛尔单药治疗24周对患者报告健康状况的影响。结果显示Aficamten组KCCQ-OSS改善显著优于美托洛尔组(校正组间差+7.8分,95%CI 3.3-12.3,P<0.001),且出现极大幅改善(≥20分)的比例更高(38.6% vs 18.4%)。

要点

  • Aficamten较美托洛尔显著改善oHCM患者24周KCCQ-OSS(+7.8分,P<0.001)。
  • Aficamten组极大幅KCCQ-OSS改善(≥20分)比例38.6%,美托洛尔组18.4%,NNT=4.9。
  • Aficamten组健康状况恶化(≤-5分)比例更低(6.8% vs 18.4%),NNH=8.6。

核心结论

  • Aficamten较美托洛尔显著改善有症状oHCM患者24周健康状况,支持其作为有效初始治疗选择。

研究设计与样本

  • MAPLE-HCM为国际、双盲、随机、头对头试验,纳入175例有症状oHCM成人患者(Aficamten组88例,美托洛尔组87例),治疗24周。

主要发现

  • Aficamten组24周KCCQ-OSS校正组间差为+7.8分(95%CI 3.3-12.3,P<0.001),优于美托洛尔组。
  • Aficamten组38.6%患者KCCQ-OSS改善≥20分,美托洛尔组18.4%(NNT=4.9,95%CI 3.0-13.9)。
  • Aficamten组6.8%患者KCCQ-OSS恶化≤-5分,美托洛尔组18.4%(NNH=8.6,95%CI 4.7-53.3)。
  • SAQ-SS组间差+4.6分(95%CI -0.3至9.5,P=0.063),SAQ体力受限维度改善+10.1分(95%CI 3.9-16.2,P=0.001)。

关键数值与推荐

  • 入组标准:有症状oHCM,KCCQ临床总结评分≤90,静息左室流出道梗阻≥30 mmHg或Valsalva动作后≥50 mmHg。
  • KCCQ-OSS变化分级:≤-5分恶化,>-5至<+5无变化,+5至<+10小幅改善,+10至<+15中度改善,+15至<+20大幅改善,≥+20极大幅改善。

临床怎么用

  • 对于有症状oHCM患者,Aficamten单药治疗24周可较美托洛尔更显著改善患者报告的健康状况。
  • Aficamten在提升极大幅改善比例和减少健康状况恶化方面均优于美托洛尔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cardiac myosin inhibitor aficamten was significantly more effective than metoprolol at improving exercise tolerance in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a head-to-head, international, double-blind, randomized trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). Given the primary treatment goal to improve patients' health status, defining the incremental benefits of aficamten over metoprolol on patients' symptoms, function, and quality of life is needed. OBJECTIVES: In this study, the authors sought to compare patient-reported health status benefits of aficamten with metoprolol. METHODS: Adults with symptomatic oHCM (Kansas City Cardiomyopathy Questionnaire [KCCQ] Clinical Summary Score [CSS] ≤90; left ventricular outflow tract obstruction ≥30 mm Hg at rest or ≥50 mm Hg with Valsalva) were randomly assigned to 24 weeks of aficamten or metoprolol as monotherapy. Changes in KCCQ Overall Summary Score (OSS) and Seattle Angina Questionnaire Summary Score (SAQ-SS), collected serially throughout the trial, were compared between treatment groups at 24 weeks using linear regression, adjusted for randomization strata and baseline scores. Individual participant experiences were described by comparing categories of clinically meaningful within-participant change: ≤-5 (worse), >-5 to <+5 (no change), +5 to <+10 (small improvement), +10 to <+15 (moderate improvement), +15 to <+20 (large improvement), and ≥+20 points (very large improvement). RESULTS: Among 175 randomized patients, baseline health status scores were similar between treatment groups (n = 88 aficamten; n = 87 metoprolol). Aficamten, compared with metoprolol, resulted in a greater 24-week KCCQ-OSS improvement (adjusted between-group difference: +7.8 points; 95% CI: 3.3-12.3; P < 0.001), primarily driven by a greater proportion of aficamten-treated (38.6%) vs metoprolol-treated (18.4%) patients experiencing a very large (≥20 points) KCCQ-OSS improvement (number needed to treat = 4.9; 95% CI: 3.0-13.9), and a smaller proportion experiencing worsening health status (≤-5-point change: 6.8% vs 18.4%; number needed to harm = 8.6; 95% CI: 4.7-53.3). Nonsignificant SAQ-SS improvements with aficamten vs metoprolol (+4.6 points; 95% CI -0.3 to 9.5 points; P = 0.063) were driven by significantly larger improvements in the SAQ Physical Limitation scale (+10.1 points; 95% CI: 3.9-16.2 points; P = 0.001). CONCLUSIONS: Aficamten improved the health status of patients with symptomatic oHCM significantly more than did metoprolol, highlighting its potential as an effective initial therapeutic option. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM; NCT05767346).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nassif ME, Garcia-Pavia P, Masri A, et al. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2025. PMID: 41493295. doi:10.1016/j.jacc.2025.10.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。